ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy

Phase 2

Active, not recruiting

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: Abatacept
Drug: Dexamethasone
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis

First Posted Date: 2018-03-07

Last Posted Date: 2024-05-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03457142

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
St. Francis Hospital, East Hills, New York, United States
🇺🇸
Good Samaritan Hospital, West Islip, New York, United States

Antioxidant Supplements, Genetics and Chemotherapy Outcomes

Completed

Conditions: Node Positive Breast Cancer
Node Negative Breast Cancer

First Posted Date: 2018-01-29

Last Posted Date: 2022-08-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1771

Registration Number: NCT03413761

Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase 2

Completed

Conditions: Metastatic Carcinoma in the Liver
Recurrent Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7

Interventions: Drug: Celecoxib
Other: Laboratory Biomarker Analysis
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2018-01-18

Last Posted Date: 2022-03-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 19

Registration Number: NCT03403634

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery

Phase 1

Suspended

Conditions: Stage IV Cutaneous Melanoma AJCC v6 and v7
Stage IIIC Cutaneous Melanoma AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Propranolol Hydrochloride

First Posted Date: 2017-12-27

Last Posted Date: 2024-11-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 47

Registration Number: NCT03384836

Locations: 🇺🇸
Emory University Hospital/ Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 1 locations

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
Blasts 30 Percent or Less of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia
High Risk Myelodysplastic Syndrome
Myelodysplastic Syndrome
Refractory Anemia

Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401
Drug: Decitabine
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Drug: Poly ICLC

First Posted Date: 2017-12-02

Last Posted Date: 2021-10-05

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT03358719

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer

Early Phase 1

Active, not recruiting

Conditions: Stage I Non-Small Cell Lung Cancer AJCC v7
Stage IB Non-Small Cell Lung Carcinoma AJCC v7
Stage II Non-Small Cell Lung Cancer AJCC v7
Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Stage IA Non-Small Cell Lung Carcinoma AJCC v7
Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
Stage IIIA Non-Small Cell Lung Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Stereotactic Body Radiation Therapy
Procedure: Thoracic Surgical Procedure

First Posted Date: 2017-11-21

Last Posted Date: 2024-05-07

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03348748

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Phase 2

Active, not recruiting

Conditions: Acute Leukemia in Remission
Acute Myeloid Leukemia
CD40 Ligand Deficiency
Chronic Lymphocytic Leukemia
Glanzmann Thrombasthenia
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Congenital Pure Red Cell Aplasia
Myelofibrosis
Paroxysmal Nocturnal Hemoglobinuria
Secondary Acute Myeloid Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2017-11-07

Last Posted Date: 2024-04-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 31

Registration Number: NCT03333486

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer

Early Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma
Stage IIB Ovarian Cancer
Stage IIIB Ovarian Cancer
Stage III Ovarian Cancer
Stage IC Ovarian Cancer
Stage IIA Ovarian Cancer
Stage IIC Ovarian Cancer
Stage I Ovarian Cancer
Stage IB Ovarian Cancer

Interventions: Procedure: Diagnostic Microscopy
Drug: Fluorescein Sodium Injection
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-09-29

Last Posted Date: 2021-10-06

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 19

Registration Number: NCT03297489

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Adult Hepatocellular Carcinoma
Stage IIIB Hepatocellular Carcinoma
Child-Pugh Class A
Stage IIIA Hepatocellular Carcinoma
Stage IIIC Hepatocellular Carcinoma
Stage IVA Hepatocellular Carcinoma
Stage III Hepatocellular Carcinoma
Stage IV Hepatocellular Carcinoma
Stage IVB Hepatocellular Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Sorafenib Tosylate

First Posted Date: 2017-07-07

Last Posted Date: 2024-07-03

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 37

Registration Number: NCT03211416

Locations: 🇺🇸
Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia in Remission
Adult Acute Lymphoblastic Leukemia in Complete Remission
Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission
Chronic Myelomonocytic Leukemia in Remission
Graft Versus Host Disease
Severe Aplastic Anemia
Hodgkin Lymphoma
Minimal Residual Disease
Myeloproliferative Neoplasm
Non-Hodgkin Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Melphalan Hydrochloride
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-06-20

Last Posted Date: 2024-05-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 35

Registration Number: NCT03192397

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy